Antisense & RNAi Therapeutics Market by Product Type, by Application, by Geography – Forecast to 2028

Report - ID613086 | 12 July, 2019 | Healthcare | 100 pages | Report Type (Global) | Publisher Name - RFM

Market Analysis Insights 
The antisense & RNAi therapeutics market is expected to grow globally with an estimated CAGR of 8.0% to reach USD 2.35 billion by 2028. Presence of strong pipeline product portfolio, implementation of favourable government initiatives & external funding for R&D exercises and rising collaborations between pharmaceutical companies are some of the main market drivers of this market. 

Market Segment
The Market is segmented based on Technology
• RNA Interference
o siRNA
o miRNA
• Antisense RNA

The Market is segmented based on Application
• Oncology
• Cardiovascular Diseases (CVDs)
• Respiratory Disorders
• Renal Diseases
• Neurodegenerative Disorders
• Genetic Disorders
• Infectious Diseases

The Market is segmented based on Route of Administration
• Pulmonary Delivery
• Intravenous Injections
• Intra-dermal Injections
• Intraperitoneal Injections
• Topical Delivery

The above segmentation is covered for all countries and regions listed below
• North and South America
o U.S.
o Canada
o Mexico
o Brazil
o Rest of Americas
• Europe
o Germany
o France
o U.K.
o Italy 
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o Rest of APAC
• Middle East and Africa
Vendor Landscape Competitive Research
The major players in antisense & RNAi therapeutics market are Sirnaomics, Inc., Santaris, Dicerna Pharmaceuticals, Inc., Silenseed LTD, Sylentis, Sarepta Therapeutics, RXi Pharmaceuticals,  Regulus Therapeutics Inc.
Leave a Message